RegulatoryCompany release

Ocugen wins provisional Bahamas nod for OCU400 and starts OCU410 Phase 3 dosing

🇺🇸 Ocugen, Inc. (OCGN) · Wed 04 Nov 2026

The US gene therapy developer also licensed OCU400 for the Middle East and North Africa and reported $84.6 million in cash alongside its third-quarter results.

Ocugen reported third-quarter results and a business update on 4 November 2026, announcing regulatory, commercial and clinical progress across its ophthalmology pipeline.

The Bahamas' LARTA Board granted provisional approval and priority designation to OCU400 for retinitis pigmentosa, according to the company. The summary available does not set out the conditions attached to the provisional status or any timetable for full approval.

Ocugen also licensed OCU400 for the Middle East and North Africa (MENA) region to Roots Pharmaceutical. Financial terms and the countries covered were not provided in the material reviewed.

In clinical development, the company dosed the first patient in ArMaDa3, a Phase 3 trial of OCU410 in geographic atrophy. Ocugen reported cash of $84.6 million, which it expects to fund operations into 2028.

What it means for your team

  • Regulatory teams tracking OCU400 should note that the Bahamian decision is provisional, so the conditions and any follow-up requirements are worth monitoring.
  • Market-access and commercial teams should watch how the MENA licence to Roots Pharmaceutical translates into regional filings and launch planning.
  • Teams following geographic atrophy should note that OCU410 has now entered Phase 3 dosing in the ArMaDa3 trial.

Company's press release (SEC filing): Ocugen, Inc. ↗

Article written by VigiEye from the official source (Ocugen, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →